Next 10 |
home / stock / crdf / crdf articles
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhib...
U.S. stocks traded lower toward the end of trading, with the S&P 500 edging lower on Monday. The Dow traded down 0.20% to 39,007.30 while the N...
Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quar...
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. Zscaler posted better-tha...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Friday. The Dow traded up 0.02% to 39,005....
Cardiff Oncology Inc (NASDAQ:CRDF) provided a clinical update on the first release of data from its ONSEMBLE trial of onvansertib in combinati...
Shares of NetApp, Inc. (NASDAQ: NTAP) shares rose sharply in today’s pre-market trading after the company reported better-than-expected thir...
- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIR...
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibi...
News, Short Squeeze, Breakout and More Instantly...
Cardiff Oncology Inc. Company Name:
CRDF Stock Symbol:
NASDAQ Market:
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a r...
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth – – Enhanced clinic...
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhib...